183 related articles for article (PubMed ID: 38154357)
1. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
2. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
3. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.
Sasaki M; Sato Y; Nakanuma Y
Virchows Arch; 2024 Mar; ():. PubMed ID: 38532197
[TBL] [Abstract][Full Text] [Related]
4. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
5. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
[TBL] [Abstract][Full Text] [Related]
6. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2023 Aug; 83(2):298-309. PubMed ID: 37140546
[TBL] [Abstract][Full Text] [Related]
7. Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma.
Chung YS; Jeon Y; Yoo JE; Chung T; Ryu HJ; Kim H; Rhee H; Park YN
Hepatol Int; 2023 Feb; 17(1):77-85. PubMed ID: 36253584
[TBL] [Abstract][Full Text] [Related]
8. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
[TBL] [Abstract][Full Text] [Related]
10. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
11. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
Nguyen Canh H; Takahashi K; Yamamura M; Li Z; Sato Y; Yoshimura K; Kozaka K; Tanaka M; Nakanuma Y; Harada K
Histopathology; 2021 Nov; 79(5):731-750. PubMed ID: 34018212
[TBL] [Abstract][Full Text] [Related]
12. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas.
Sawada R; Ku Y; Akita M; Otani K; Fujikura K; Itoh T; Ajiki T; Fukumoto T; Kakeji Y; Zen Y
Histopathology; 2018 Aug; 73(2):259-272. PubMed ID: 29675965
[TBL] [Abstract][Full Text] [Related]
14. Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.
Chung T; Rhee H; Shim HS; Yoo JE; Choi GH; Kim H; Park YN
Gut Liver; 2022 Jul; 16(4):613-624. PubMed ID: 34810298
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
16. Pathology of Cholangiocarcinomas.
Guedj N
Curr Oncol; 2022 Dec; 30(1):370-380. PubMed ID: 36661679
[TBL] [Abstract][Full Text] [Related]
17. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.
Rhee H; Kim MJ; Park YN; An C
Eur Radiol; 2019 Jun; 29(6):3111-3121. PubMed ID: 30560357
[TBL] [Abstract][Full Text] [Related]
18. Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations.
Gerber TS; Müller L; Bartsch F; Gröger LK; Schindeldecker M; Ridder DA; Goeppert B; Möhler M; Dueber C; Lang H; Roth W; Kloeckner R; Straub BK
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804931
[TBL] [Abstract][Full Text] [Related]
19. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
20. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling.
Wei Y; Chen W; Li Z; Xie K; Liu F
FASEB J; 2022 Dec; 36(12):e22647. PubMed ID: 36350008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
